P&G Health Sees Flat Q2, Raises Caution from Analysts

Procter & Gamble Health Ltd reported flat quarterly financial trends in its latest quarter, ending June 2026. The company's financial trend score dropped sharply from 10 to 3 over the past three months, indicating a flattening of growth momentum.

Despite this moderation, Procter & Gamble Health Ltd posted a robust earnings per share (EPS) of ₹57.92, marking its highest quarterly figure to date. The profit after tax (PAT) for the last six months grew by an impressive 31.18% to ₹167.07 crores.

The company's recent financial trend may be indicative of broader sectoral challenges, including pricing pressures and increased R&D expenditure. Nevertheless, its ability to sustain strong profitability metrics such as EPS and PAT growth suggests operational efficiencies and a solid product portfolio.

Looking ahead, Procter & Gamble Health Ltd's ability to reinvigorate its revenue growth and expand margins will be critical to reversing the recent flattening of its financial trend. The company's strong EPS and PAT growth provide a foundation for optimism, but investors should remain cautious given the downgrade in its Mojo Grade and the current market volatility reflected in its share price movements.